Role of biological agents inflammatory diseases

被引：29

作者：

Efthimiou, P ^{[1
]}

Markenson, JA ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA

来源：

SOUTHERN MEDICAL JOURNAL | 2005年 / 98卷 / 02期

关键词：

biological therapy; IL-1 receptor antagonist; psoriatic arthritis; rheumatoid arthritis; TNF-alpha inhibitors;

D O I：

10.1097/01.SMJ.0000153119.37032.8B

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new era in the treatment of immune-mediated inflammatory disorders has begun with the clinical availability of anticytokine therapy. Biological agents that are currently available include 3 agents that decrease the activity of tumor necrosis factor-alpha (infliximab, adalimumab, etanercept) and an interleukin-1 receptor antagonist (anakinra), with many more in development. Those extraordinarily effective medications are an important addition to our therapeutic armamentarium, and, although originally developed for rheumatoid arthritis and Crohn disease, have been found to be efficacious in the treatment of seronegative spondyloarthropathies (psoriatic arthritis, ankylosing spondylitis) and juvenile rheumatoid arthritis. Their role is currently being defined in other autoimmune disorders such as uveitis, sarcoidosis, interstitial lung disease, vasculitis, inflammatory myopathies, graft-versus-host disease, and Sjogren syndrome.

引用

页码：192 / 204

页数：13

共 105 条

[11] Therapy of ankylosing spondylitis and other spondyloarthritides:: established medical treatment, anti-TNF-α therapy and other novel approaches [J].

Braun, J ;

Sieper, J .

ARTHRITIS RESEARCH, 2002, 4 (05) :307-321

[12] Efficacy of infliximab in refractory ankylosing spondylitis:: results of a six-month open-label study [J].

Breban, M ;

Vignon, E ;

Claudepierre, P ;

Devauchelle, V ;

Wendling, D ;

Lespessailles, E ;

Euller-Ziegler, L ;

Sibilia, J ;

Perdriger, A ;

Mezières, M ;

Alexandre, C ;

Dougados, M .

RHEUMATOLOGY, 2002, 41 (11) :1280-1285

[13]

Breedveld FC, 2003, ARTHRITIS RHEUM, V48, pS118

[14]

BRENNAN FM, 1989, LANCET, V2, P244

[15]

Bresnihan B, 2002, CLIN EXP RHEUMATOL, V20, pS32

[16]

Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO

[17]

2-2

[18] Effects of a PEGylated soluble TNF receptor type 1 (PEG sTNF-RI) on cytokine expression in adjuvant arthritis [J].

Bush, KA ;

Walker, JS ;

Frazier, J ;

Kirkham, BW .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2002, 31 (04) :198-204

[19]

Calamia KT, 2003, ADV EXP MED BIOL, V528, P545

[20]

CAVANAUGH A, 2003, FDAA M 2003 UPD SAF

← 1 2 3 4 5 6 7 8 9 10 →